RT Journal Article
T1 Patient, tumor, and healthcare factors associated with regional variability in lung cancer survival: a Spanish high-resolution population-based study.
A1 Rodriguez-Barranco, M
A1 Salamanca-Fernandez, E
A1 Fajardo, M L
A1 Bayo, E
A1 Chang-Chan, Y-L
A1 Exposito, J
A1 Garcia, C
A1 Tallon, J
A1 Minicozzi, P
A1 Sant, M
A1 Petrova, D
A1 Luque-Fernandez, M A
A1 Sanchez-Perez, Maria-Jose
K1 Cancer treatment
K1 Excess risk
K1 Hospital medical records
K1 Lung cancer
K1 Population-based cancer epidemiology
K1 Survival analysis
AB The third most frequently diagnosed cancer in Europe in 2018 was lung cancer; it is also the leading cause of cancer death in Europe. We studied patient and tumor characteristics, and patterns of healthcare provision explaining regional variability in lung cancer survival in southern Spain. A population-based cohort study included all 1196 incident first invasive primary lung cancer (C33-C34 according to ICD-10) cases diagnosed between 2010 and 2011 with follow-up until April 2015. Data were drawn from local population-based cancer registries and patients' hospital medical records from all public and private hospitals from two regions in southern Spain. There was evidence of regional differences in lung cancer late diagnosis (58% stage IV in Granada vs. 65% in Huelva, p value  The observed geographic differences in survival between regions are due in part to the late cancer diagnosis which determines the use of less effective therapeutic options. Results from our study justify the need for promoting lung cancer early detection strategies and the harmonization of the best practice in lung cancer management and treatment.
PB Springer Milano
YR 2018
FD 2018-10-08
LK http://hdl.handle.net/10668/13110
UL http://hdl.handle.net/10668/13110
LA en
NO Rodríguez-Barranco M, Salamanca-Fernández E, Fajardo ML, Bayo E, Chang-Chan YL, Expósito J, et al. Patient, tumor, and healthcare factors associated with regional variability in lung cancer survival: a Spanish high-resolution population-based study. Clin Transl Oncol. 2019 May;21(5):621-629.
NO s Maria Jose Sanchez Perez is supported by theAndalusian Department of Health: Research, Development, and Innovation Ofce project grant PI-0152/2017. Miguel Angel Luque-Fernandez is supported by the Spanish National Institute of Health, Carlos IIIMiguel Servet I Investigator Award (CP17/00206).
DS RISalud
RD Apr 12, 2025